Last reviewed · How we verify
Etravirine Tablets
Non-nucleoside reverse transcriptase inhibitor
Non-nucleoside reverse transcriptase inhibitor Used for HIV-1 infection.
At a glance
| Generic name | Etravirine Tablets |
|---|---|
| Sponsor | IRCCS Eugenio Medea |
| Drug class | Non-nucleoside reverse transcriptase inhibitor |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits the replication of HIV-1 by binding to the reverse transcriptase enzyme.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants (PHASE1)
- Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (PHASE2)
- Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) (PHASE1)
- Optimizing Treatment for Treatment-Experienced, HIV-Infected People (PHASE3)
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etravirine Tablets CI brief — competitive landscape report
- Etravirine Tablets updates RSS · CI watch RSS
- IRCCS Eugenio Medea portfolio CI